The Triple Lock trip up, take two

There is a threat to the triple lock on state pensions

State pension increases and the Triple Lock are back in the spotlight. About a year ago, during the first wave of the pandemic, several think tanks started to look at the potential repercussions of the then crumbling economy on state pensions. Their particular focus was on the ‘Triple Lock’, which applies only to payments made…

Read More

The £9 billion Child Trust Funds backwater

Child Trust Funds are largely forgotten

Over £9 billion was invested in Child Trust Funds (CTFs) as of April 2020, according to new HMRC data. If you have a child or grandchild born between 1 September 2002 and 2 January 2011, they were almost certainly the beneficiary of a government payment – either £250 or £500 – into a CTF. The…

Read More

Cash ISAs remain dominant: The wrong type of ISA?

Cash ISAs are the dominant form of ISA saving

New statistics from HMRC show over £300bn invested in cash ISAs. One of the many knock-on effects of the pandemic has been that HMRC’s annual updating of statistics has suffered delays. As a result, details of ISA subscriptions and holdings for 2019/20 have only just emerged. Among many interesting facts, the data shows: Despite ultra-low…

Read More

How much pension?? What is an adequate retirement income?

Planning your retirement income is not straightforward

A leading pension think tank has examined this question – but the findings aren’t straightforward. Over the years, there has been much focus on the tax treatment of pensions and ways to encourage greater saving for retirement. Arguably, there has been less attention paid to the question of how much income you will need once…

Read More

The year so far for investors: six months down…

what does the rest of the year hold for investors?

The first six months of 2021 have been rewarding for investors, but the next six are uncertain.  The first half of 2021 was a much less traumatic ride for investors than the first half of 2020. With hindsight, last November’s Pfizer/BioNTech vaccine breakthrough announcement gave investment markets a fresh momentum that continued through the first two quarters…

Read More